Cardioplegia solutions that prevent heart cell swelling

• US 5,139,789 A
• Filed: 10/17/1990
• Issued: 08/18/1992
• Est. Priority Date: 10/17/1990
• Status: Expired due to Fees

• Current Assignee: Virginia Commonwealth University
• Original Assignee: The Center For Innovative Technology, Virginia Commonwealth University
• Inventors: Baumgarten, Clive M.
• Primary Examiner(s): Raymond, Richard L.
• Assistant Examiner(s): RUSSELL, MARK
• Application Number:
  US07/599,014
• Time in Patent Office: 671 Days
• Field of Search: 414/677, 414/678, 414/679, 414/680, 414/681
• US Class Current: 424/678
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/185 Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids hydroxamic acids A61K31/16; peroxy acids A61K31/327
• CPC Class Codes: A61K 33/00 Medicinal preparations containing inorganic active ingredients
• CPC Class Codes: A61K 33/14 Alkali metal chlorides; Alkaline earth metal chlorides

Abstract

Cardioplegia solutions having potassium and chloride ion concentrations selected to give a product approximately equal to the product of the potassium and chloride ion concentrations in blood and blood substitutes have been shown to prevent heart cell swelling during cardioplegia.

Claims

1. A cardioplegia solution comprised of a mixture of sodium methanesulfonate, sodium bicarbonate, magnesium chloride, potassium chloride, potassium methanesulfonate, and calcium chloride, wherein the concentrations of said sodium methanesulfonate, sodium bicarbonate, magnesium chloride, potassium chloride potassium methanesulfonate, and calcium chloride are chosen such that said cardioplegia solution includes potassium ions of a first concentration and chloride ions of a second concentration and a product of said first concentration of potassium ions and said second concentration of chloride ions in said cardioplegia solution is approximately equal to the product of the concentrations of potassium and chloride ions in a patient'"'"'s blood, said potassium ion concentration in said cardioplegia solution being greater than said potassium ion concentration in said patient'"'"'s blood, said chloride ion concentration in said cardioplegia solution being less than said chloride ion concentration in said patient'"'"'s blood.

2. A cardioplegia solution as recited in claim 1 wherein said product ranges between 350 mM² and 700 mM².

3. A cardioplegia solution as recited in claim 1 wherein said potassium ion concentration is 16 mM.

4. The cardioplegia solution of claim 1 wherein said potassium ion concentration is at least 16 mM.

5. A method of adapting an existing cardioplegia solution including potassium ions of a first concentration and chloride ions of a second concentration to produce a second cardioplegia solution with a third concentration of potassium ions and a fourth concentration of chloride ions which exhibits reduced heart cell swelling, comprising the step of substituting constituents with chloride anions in said existing cardioplegia solution with constituents not having chloride anions thereby producing said second cardioplegia solution in which a product of said third concentration of potassium ions and said fourth concentration of chloride ions in said cardioplegia solution is approximately equal to the product of the concentrations of potassium ions and chloride ions in a patient'"'"'s blood, said potassium ion concentration in said cardioplegia solution being greater than said potassium ion concentration in said patient'"'"'s blood, said chloride ion concentration in said cardioplegia solution being less than said chloride ion concentration in said patient'"'"'s blood.

6. A method as recited in claim 5 wherein said first concentration of potassium ions in said existing cardioplegia solution and said third concentration of potassium ions in said second cardioplegia solution produced by said step of substituting are equivalent.

7. A method of using cardioplegia solutions for surgery and organ transport, comprising the steps of:

determining a potassium ion concentration and a chloride ion concentration in a patient'"'"'s blood;

calculating a product of said potassium ion concentration and said chloride ion concentration in said patient'"'"'s blood; and

matching a cardioplegia solution capable of interrupting myocardium contractions to said product of said potassium ion concentration and said chloride ion concentration in said patient'"'"'s blood by having said cardioplegia solution include a potassium ion concentration and chloride ion concentration with a product approximately equivalent to said product of said potassium ion concentration and said chloride ion concentration in said patient'"'"'s blood, said potassium ion concentration in said cardioplegia solution being greater than said potassium ion concentration in said patient'"'"'s blood, said chloride ion concentration in said cardioplegia solution being less than said chloride ion concentration in said patient'"'"'s blood.

8. A method as recited in claim 7 wherein said step of matching includes the step of using anions which are poorly permeable to cardiac cell membrane and have a low pKa to reduce said chloride ion in said cardioplegia solution.

9. A method of using cardioplegia solutions for surgery and organ transport, comprising the steps of:

determining a potassium ion concentration and a chloride ion concentration in a physiologic blood substitute;

calculating a product of said potassium ion concentration and said chloride ion concentration in said physiologic blood substitute; and

matching a cardioplegia solution capable of interrupting myocardium contractions to said product of said potassium ion concentration and said chloride ion concentration in said physiologic blood substitute by having said cardioplegia solution include a potassium ion concentration and chloride ion concentration with a product approximately equivalent to said product of said potassium ion concentration and said chloride ion concentration in said physiologic blood substitute, said potassium ion concentration in said cardioplegia solution being greater than said potassium ion concentration in said physiologic blood substitute, said chloride ion concentration in said cardioplegia solution being less than said chloride ion concentration in said physiologic blood substitute.

10. A method as recited in claim 9 wherein said step of matching includes the step of using anions which are poorly permeable to cardiac cell membrane and have a low pKa to reduce said chloride ion in said cardioplegia solution.